A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

2023-506402-39-00 Protocol HFB-301001-01 Human pharmacology (Phase I) - First administration to humans Ended

Start 27 Jul 2022 · End 13 Oct 2025 · Status Ended · 1 EU/EEA countries · 3 sites · Protocol HFB-301001-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 170
Countries 1
Sites 3

Advanced cancer of different organs

Key facts

Sponsor
Hifibio Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
27 Jul 2022 → 13 Oct 2025
Decision date (initial)
2023-08-30
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-506402-39-00
EudraCT number
2021-004854-46
WHO UTN
U1111-1295-8492
ClinicalTrials.gov
NCT05229601

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced cancer of different organs

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Hifibio Inc.

Sponsor organisation
Hifibio Inc.
Address
237 Putnam Avenue
City
Cambridge
Postcode
02139-3807
Country
United States

Scientific contact point

Organisation
Hifibio Inc.
Contact name
Sami Ellouze

Public contact point

Organisation
Hifibio Inc.
Contact name
HIFIBIO Clinical

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 70 3
Rest of world
United States
100

Investigational sites

Spain

3 sites · Ended
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitari Vall D Hebron
Oncology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital Universitario 12 De Octubre
Oncology, Bloque D, Avenida De Cordoba Sn, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2022-07-27 2022-08-25 2024-04-10

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-44142

Halt date
2024-08-30
Member states concerned
Spain
Publication date
2024-09-04
Reason
Sponsor decision
Benefit-risk balance changed
No
Treatment stopped
Yes

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-08-25 Spain Acceptable
2023-08-30
2023-08-30
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-03-07 Spain Acceptable
2023-08-30
2024-03-07
3 SUBSTANTIAL MODIFICATION SM-1 2025-02-06 Spain Acceptable
2025-03-12
2025-03-12